Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?

Lopez-Crapez E, Mineur L, Emptas H, Lamy PJ.

Br J Cancer. 2010 Mar 16;102(6):1074-5; author reply 1076-7. doi: 10.1038/sj.bjc.6605582. Epub 2010 Feb 16. No abstract available.

2.

Targeting EGFR in colorectal cancer.

Messersmith WA, Ahnen DJ.

N Engl J Med. 2008 Oct 23;359(17):1834-6. doi: 10.1056/NEJMe0806778. No abstract available.

PMID:
18946069
3.

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer.

Di Fiore F, Charbonnier F, Lefebure B, Laurent M, Le Pessot F, Michel P, Frebourg T.

Br J Cancer. 2008 Aug 5;99(3):551-2. doi: 10.1038/sj.bjc.6604451. Epub 2008 Jul 1. No abstract available.

4.

[Prognostic role of KRAS mutation in colorectal cancer].

Di Fiore F, Michel P.

Bull Cancer. 2009 Dec;96 Suppl:S23-30. doi: 10.1684/bdc.2009.0994. French.

PMID:
20034867
5.

Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.

Kendall A, Lord R, Maisey N.

Recent Pat Anticancer Drug Discov. 2010 Jun;5(2):142-51. Review.

PMID:
19954416
6.

BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer.

Mao C, Liao RY, Chen Q.

J Cancer Res Clin Oncol. 2010 Aug;136(8):1293-4. doi: 10.1007/s00432-010-0922-8. Epub 2010 Jun 1. No abstract available.

PMID:
20514492
7.

New strategies for treatment of KRAS mutant metastatic colorectal cancer.

Prenen H, Tejpar S, Van Cutsem E.

Clin Cancer Res. 2010 Jun 1;16(11):2921-6. doi: 10.1158/1078-0432.CCR-09-2029. Epub 2010 May 11. Review.

8.

Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.

Lee D.

Clin Colorectal Cancer. 2004 Sep;4(3):159-62. Review. No abstract available.

PMID:
15377399
9.

Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.

Dempke WC, Heinemann V.

Anticancer Res. 2010 Nov;30(11):4673-7. Review.

PMID:
21115922
11.

Responsiveness to cetuximab without mutations in EGFR.

Tsuchihashi Z, Khambata-Ford S, Hanna N, Jänne PA.

N Engl J Med. 2005 Jul 14;353(2):208-9. No abstract available.

12.

Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine.

Shi C, Washington K.

Am J Clin Pathol. 2012 Jun;137(6):847-59. doi: 10.1309/AJCPI83DINULUJNI.

PMID:
22586043
13.

[Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view].

Bibeau F, Frugier H, Denouel A, Sabourin JC, Boissiere-Michot F.

Bull Cancer. 2009 Dec;96 Suppl:S15-22. doi: 10.1684/bdc.2009.0993. French.

PMID:
20034866
14.
15.

Cetuximab for colorectal cancer.

Yang F, Fu D, Ni Q.

N Engl J Med. 2008 Mar 13;358(11):1195; author reply 1196-7. doi: 10.1056/NEJMc073415. No abstract available.

16.

[Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view].

Blons H, Laurent-Puig P.

Bull Cancer. 2009 Dec;96 Suppl:S47-56. doi: 10.1684/bdc.2009.0996. Review. French.

PMID:
20034870
17.

Cetuximab for colorectal cancer.

Fraggetta F, Pelosi G.

N Engl J Med. 2008 Mar 13;358(11):1196; author reply 1196-7. No abstract available.

PMID:
18340663
18.

KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?

Zhang W, Labonte MJ, Lenz HJ.

Ann Oncol. 2011 Feb;22(2):484-5. doi: 10.1093/annonc/mdq704. Epub 2011 Jan 28. No abstract available.

PMID:
21278223
19.

Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report.

Osumi H, Matsusaka S, Shinozaki E, Suenaga M, Mingyon M, Saiura A, Ueno M, Mizunuma N, Yamaguchi T.

BMC Res Notes. 2013 Dec 5;6:508. doi: 10.1186/1756-0500-6-508.

20.

K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer.

Eng C.

Clin Adv Hematol Oncol. 2008 Mar;6(3):174-5. Review. No abstract available.

PMID:
18391915

Supplemental Content

Support Center